SEO URLwww.firestrike.ai/deals/scpharmaceuticals-mannkind-acquisition-2026
acquisitionAnnounced · Feb 7, 2026cardiometabolicSource · AdvertisementsArticle · Expectations
MannKind acquires scPharmaceuticals
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$290M
Target
scPharmaceuticals
Burlington, Massachusetts
Acquirer
MannKind
Full Acquisition
Status
Announced
MannKind agreed to acquire scPharmaceuticals. Reported deal value: $290M. Status: Announced. Sector: cardiometabolic. Target headquarters context: Burlington, Massachusetts, United States.
This page summarizes publicly available information about the transaction as of 2026-02-07. Figures and status may change as filings and press coverage update.
Foto: über boerse-global.de The investment landscape for scPharmaceuticals shifted fundamentally in October 20 25 , following its acquisition by MannKind Corporation
Deal timeline
Announced
Feb 7, 2026 · ad-hoc-news.de
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in cardiometabolic with a reported deal value of $290M. Figures and status may change as sources update.
Sources: ad-hoc-news.de · Primary article · FireStrike proprietary index